| Active substance | Ibrutinib |
| Holder | Janssen-Cilag |
| Status | Running |
| Indication | in combination with R-CHOP alternating with R-DHAP (or R-DHAOx), followed by ibrutinib monotherapy, for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantation (ASCT) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 04/03/2026 |